Thrombopoietin Receptor Agonists and Other Second-Line Therapies for Immune Thrombocytopenia: A Narrative Review With a Focus on Drug Access in Canada
DISCUSSION: TPO-RAs are effective second-line therapies for the treatment of ITP; however, access is variable across Canada, which results in health disparities and poor uptake of international treatment guidelines.PMID:38546381 | DOI:10.3138/cim-2024-2569
Source: Clinical and Investigative Medicine - Category: Biomedical Science Authors: Joanne Britto Anne Holbrook Haowei Sun Christine Cserti-Gazdewich Oksana Prokopchuk-Gauk Cyrus Hsia Karima Khamisa Paul R Yenson Michelle Sholzberg Harold J Olney Sudeep Shivakumar David Jones Hayley Merkeley Jacqueline Costello Erin Jamula Donald M Arnol Source Type: research
More News: Autoimmune Disease | Biomedical Science | Bleeding | Canada Health | Corticosteroid Therapy | Funding | Gammagard Liquid | Health Management | Privigen | Rituxan | Splenectomy | Study | Thrombocytopenia